Gastric Cancer Diagnostics - Global Strategic Business Report

The global market for Gastric Cancer Diagnostics was valued at US$2.4 Billion in 2024 and is projected to reach US$3.0 Billion by 2030, growing at a CAGR of 3.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Gastric Cancer Diagnostics market.

Global Gastric Cancer Diagnostics Market - Key Trends & Drivers Summarized

Why Are Advances in Gastric Cancer Diagnostics Crucial for Early Detection and Better Prognosis?

The early detection of gastric cancer is a major challenge, as symptoms often do not appear until the disease has progressed to later stages, leading to poor prognosis and low survival rates. However, advancements in gastric cancer diagnostics are changing the landscape, making it possible to detect the disease at earlier, more treatable stages. As a result, there has been a growing emphasis on developing diagnostic technologies that can identify gastric cancer before it reaches advanced stages. The evolution of imaging techniques, such as endoscopic ultrasound (EUS) and positron emission tomography (PET), has greatly improved the ability to detect gastric tumors and assess their spread. Moreover, biomarker testing is becoming increasingly prominent in the diagnostic process. Researchers have identified a range of biomarkers associated with gastric cancer, includingHER2,p53, andCA 19-9, which are helping clinicians to detect the disease more accurately and to personalize treatment plans based on molecular profiles. Liquid biopsy, a non-invasive testing method that analyzes tumor DNA from blood samples, is another breakthrough that is advancing diagnostic capabilities. This approach enables early-stage detection and monitoring of treatment response without the need for invasive procedures. These innovations are crucial as they not only improve the chances of early detection but also offer better chances for curative treatment, significantly enhancing patient outcomes and survival rates. With growing recognition of the importance of early-stage diagnostics, there has been increased investment in research and development, further driving innovation in gastric cancer detection.

How Are Technological Innovations Transforming Gastric Cancer Diagnostics?

Technological innovations are playing a pivotal role in transforming gastric cancer diagnostics, making them more efficient, accurate, and accessible. One of the most significant developments has been the advancement in imaging technologies. Endoscopy, combined with high-definition cameras and advanced imaging techniques like narrow-band imaging (NBI) and confocal laser endomicroscopy (CLE), has improved the ability to visualize gastric tumors and precancerous lesions at the cellular level. These technologies allow for earlier detection of abnormal growths and enable more precise biopsies, improving the accuracy of diagnostic results. Furthermore, the advent of artificial intelligence (AI) and machine learning (ML) has significantly enhanced the analysis of diagnostic imaging, enabling more rapid and accurate identification of gastric cancer. AI algorithms can now be trained to detect subtle patterns in imaging data that may be missed by human eyes, helping radiologists and pathologists make faster and more accurate diagnoses. Molecular diagnostics are also seeing rapid growth, with advances in next-generation sequencing (NGS) technology allowing for comprehensive genetic profiling of gastric cancer. This approach provides valuable insights into tumor mutations and gene expression, which can guide targeted therapy and improve patient outcomes. Additionally, liquid biopsy technology, which involves analyzing circulating tumor DNA (ctDNA) from blood samples, is revolutionizing non-invasive diagnostics. This method offers a simpler, less invasive alternative to traditional biopsy procedures and holds promise for detecting gastric cancer in its earliest, most treatable stages. These technological breakthroughs are not only improving the speed and accuracy of gastric cancer diagnosis but are also laying the groundwork for more personalized treatment options.

What Are the Key Factors Driving the Demand for Gastric Cancer Diagnostic Solutions?

The growing demand for gastric cancer diagnostic solutions is driven by several factors, including the rising global incidence of gastric cancer, advancements in healthcare infrastructure, and the increasing focus on early detection and personalized medicine. The incidence of gastric cancer is expected to rise in many regions, particularly in East Asia, Central Europe, and parts of Latin America, due to factors such as diet,Helicobacter pylori infection, and genetic predisposition. As the global healthcare system recognizes the importance of early cancer detection, the demand for more advanced diagnostic technologies is increasing. Moreover, the increasing adoption of non-invasive and minimally invasive diagnostic techniques, such as liquid biopsy and endoscopic screening, is making gastric cancer detection more accessible and cost-effective for patients and healthcare providers alike. Governments and health organizations worldwide are also pushing for improved cancer screening programs, especially in high-risk populations, which is further fueling demand for gastric cancer diagnostics. The growth of healthcare infrastructure in emerging markets is another key factor. As developing regions gain access to advanced diagnostic tools, there is a greater focus on cancer prevention, early detection, and treatment. Personalized medicine is another driver of the market, as genetic testing and molecular profiling of tumors are becoming more common to identify the most effective treatment strategies for each patient. Furthermore, as public awareness of gastric cancer increases, there is greater demand for diagnostics that can detect the disease in its early stages before it spreads, which ultimately leads to better outcomes. All these factors combined are driving the increasing demand for gastric cancer diagnostic solutions.

What Are the Key Drivers Behind the Growth of the Gastric Cancer Diagnostics Market?

The growth of the gastric cancer diagnostics market is driven by a combination of factors related to medical advancements, increasing global healthcare investment, and rising awareness of the disease. As the prevalence of gastric cancer continues to rise, particularly in high-risk regions, there is an increased focus on early detection methods that can significantly improve prognosis. Early detection remains one of the most important factors in improving survival rates, which has led to a surge in demand for advanced diagnostic solutions that can identify the disease before it progresses to later, harder-to-treat stages. The rapid development of molecular and genetic diagnostics is another key driver, as researchers and clinicians now have the tools to more accurately profile tumors and tailor treatments to individual patients. The introduction of liquid biopsy as a non-invasive diagnostic tool is further transforming the landscape by offering a method for detecting gastric cancer earlier and more safely than traditional biopsies. Additionally, advancements in imaging technology, including AI-powered imaging systems and high-definition endoscopy, are providing more accurate and detailed assessments of gastric tissue, allowing for improved detection of abnormal growths and early-stage tumors. Furthermore, as healthcare systems across the globe continue to modernize, especially in emerging markets, access to these cutting-edge diagnostic tools is becoming more widespread. The increased recognition of the importance of gastric cancer screening, particularly in high-risk populations, has driven both public and private investments in diagnostic technologies. In addition to technological developments, the growing focus on personalized treatment plans that leverage genetic and molecular data has spurred the demand for diagnostics that can provide more precise and tailored treatment options. With these factors driving innovation and adoption, the gastric cancer diagnostics market is poised for continued growth, offering the potential for better outcomes and survival rates for patients worldwide.

Report Scope

The report analyzes the Gastric Cancer Diagnostics market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Product (Reagents & Consumables, Instruments); Disease Type (Adenocarcinoma, Gastric Lymphoma, Other Disease Types); End-User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers).

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Reagents & Consumables segment, which is expected to reach US$2.0 Billion by 2030 with a CAGR of a 2.8%. The Instruments segment is also set to grow at 4.8% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $664.5 Million in 2024, and China, forecasted to grow at an impressive 6.3% CAGR to reach $591.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Gastric Cancer Diagnostics Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Gastric Cancer Diagnostics Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Gastric Cancer Diagnostics Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, Agilent Technologies, Inc., BD (Becton, Dickinson and Company), Bio-Rad Laboratories, Inc., bioMérieux SA and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 42 companies featured in this Gastric Cancer Diagnostics market report include:

• Abbott Laboratories
• Agilent Technologies, Inc.
• BD (Becton, Dickinson and Company)
• Bio-Rad Laboratories, Inc.
• bioMérieux SA
• Biohit Oyj
• CD Genomics
• DiaSorin S.p.A.
• Exalenz Bioscience Ltd.
• FUJIFILM Holdings Corporation
• GeneMatrix Inc.
• Guardant Health, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Invitae Corporation
• Labcorp Oncology
• Myriad Genetics, Inc.
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• QIAGEN N.V.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What's Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry